Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies

References

• Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021). Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules, 26(21), 6677. https://doi.org/10.3390/molecules26216677
   PubMed Web of Science ®Google Scholar
• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Alam, A., Agrawal, G. P., Khan, S., Khalilullah, H., Saifullah, M. K., & Arshad, M. F. (2022). Towards the discovery of potential RdRp inhibitors for the treatment of COVID-19: Structure guided virtual screening, computational ADME and molecular dynamics study. Structural Chemistry, 33(5), 1569–1583. https://doi.org/10.1007/s11224-022-01976-2
   PubMed Web of Science ®Google Scholar
• Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011). Treatment of HER2-positive breast cancer: Current status and future perspectives. Nature Reviews. Clinical Oncology, 9(1), 16–32. https://doi.org/10.1038/nrclinonc.2011.177
   PubMed Web of Science ®Google Scholar
• Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., & Hubert, P. (2004). Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 50(1), 23–38. https://doi.org/10.1016/j.critrevonc.2003.08.004
   PubMed Web of Science ®Google Scholar
• BIOVIA & Dassault Systèmes (2020). Discovery studio visualizer, v20.1.0.19295. Dassault Systèmes. Retrieved from https://discover.3ds.com/discovery-studio-visualizer-download
   Google Scholar
• Claudiani, S., & Apperley, J. F. (2018). The argument for using imatinib in CML. Hematology. American Society of Hematology. Education Program, 2018(1), 161–167. https://doi.org/10.1182/asheducation-2018.1.161
   PubMedGoogle Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. https://doi.org/10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. https://doi.org/10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• Grassot, J., Mouchiroud, G., & Perrière, G. (2003). RTKdb: Database of receptor tyrosine kinase. Nucleic Acids Research, 31(1), 353–358. https://doi.org/10.1093/nar/gkg036
   PubMed Web of Science ®Google Scholar
• Hao, D., & Rowinsky, E. K. (2002). Inhibiting signal transduction: Recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Investigation, 20(3), 387–404. https://doi.org/10.1081/cnv-120001184
   PubMed Web of Science ®Google Scholar
• Imran, M., Abida, Alotaibi, N. M., Thabet, H. K., Alruwaili, J. A., Asdaq, S. M. B., Eltaib, L., Kamal, M., Alshammari, A. B. H., Alshammari, A. M. A., & Alshehri, A. (2023). Computer-assisted discovery of safe and effective DprE1/aaRSs inhibitors against TB utilizing drug repurposing approach. Journal of Infection and Public Health, 16(4), 554–572. https://doi.org/10.1016/j.jiph.2023.02.005
   PubMed Web of Science ®Google Scholar
• Khan, F. I., Ali, S., Chen, W., Anjum, F., Shafie, A., Hassan, M. I., & Lai, D. (2021). High-resolution MD simulation studies to get mechanistic insights into the urea-induced denaturation of human sphingosine kinase 1. Current Topics in Medicinal Chemistry, 21(31), 2839–2850. https://doi.org/10.2174/1568026621666211105095731
   PubMed Web of Science ®Google Scholar
• Khan, F. I., Hassan, F., & Lai, D. (2021). In silico studies on psilocybin drug derivatives against SARS-CoV-2 and cytokine storm of human interleukin-6 receptor. Frontiers in Immunology, 12, 794780. https://doi.org/10.3389/fimmu.2021.794780
   PubMed Web of Science ®Google Scholar
• Khan, F. I., Kang, T., Ali, H., & Lai, D. (2021). Remdesivir strongly binds to RNA-dependent RNA polymerase, membrane protein, and main protease of SARS-CoV-2: indication from molecular modeling and simulations [published correction appears in Front Pharmacol. 2022 Sep 16;13:1027099]. Frontiers in Pharmacology, 12, 710778. https://doi.org/10.3389/fphar.2021.710778
   PubMed Web of Science ®Google Scholar
• Khan, F. I., Lai, D., Anwer, R., Azim, I., & Khan, M. K. A. (2020). Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 172–186. https://doi.org/10.1080/14756366.2019.1692828
   PubMed Web of Science ®Google Scholar
• Li, E., & Hristova, K. (2010). Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adhesion & Migration, 4(2), 249–254. https://doi.org/10.4161/cam.4.2.10725
   PubMed Web of Science ®Google Scholar
• Mahapatra, M. K., & Karuppasamy, M. (2022). Chapter 2 – Fundamental considerations in drug design. In M. Rudrapal & C. Egbuna (Eds.), Drug discovery update, computer aided drug design (CADD): From ligand-based methods to structure-based approaches (pp. 17–55). Elsevier. https://doi.org/10.1016/B978-0-323-90608-1.00005-8
   Google Scholar
• Martyna, G. J., Tobias, D. J., & Klein, M. L. (1994). Constant pressure molecular dynamics algorithms. The Journal of Chemical Physics, 101(5), 4177–4189. https://doi.org/10.1063/1.467468
   Web of Science ®Google Scholar
• Metibemu, D. S., Akinloye, O. A., Akamo, A. J., Ojo, D. A., Okeowo, O. T., & Omotuyi, I. O. (2019). Exploring receptor tyrosine kinases inhibitors in Cancer treatments. Egyptian Journal of Medical Human Genetics, 20(1). https://doi.org/10.1186/s43042-019-0035-0
   Google Scholar
• Mok, T. S. (2011). Personalized medicine in lung cancer: What we need to know. Nature Reviews. Clinical Oncology, 8(11), 661–668. https://doi.org/10.1038/nrclinonc.2011.126
   PubMed Web of Science ®Google Scholar
• O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open babel: An open chemical toolbox. Journal of Cheminformatics, 3(1), 33. https://doi.org/10.1186/1758-2946-3-33
   PubMed Web of Science ®Google Scholar
• Ocana, A., Serrano, R., Calero, R., & Pandiella, A. (2009). Novel tyrosine kinase inhibitors in the treatment of cancer. Current Drug Targets, 10(6), 575–576. https://doi.org/10.2174/138945009788488378
   PubMed Web of Science ®Google Scholar
• Organic Chemistry Portal (2022). Retrieved August, 2022, from http://www.organic-chemistry.org/prog/peo/
   Google Scholar
• Polamreddy, P., & Gattu, N. (2019). The drug repurposing landscape from 2012 to 2017: Evolution, challenges, and possible solutions. Drug Discovery Today, 24(3), 789–795. https://doi.org/10.1016/j.drudis.2018.11.022
   PubMed Web of Science ®Google Scholar
• Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., Hess, B., & Lindahl, E. (2013). GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 29(7), 845–854. https://doi.org/10.1093/bioinformatics/btt055
   PubMed Web of Science ®Google Scholar
• Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• PyRx 0.8 (n.d.). Retrieved from https://pyrx.sourceforge.io
   Google Scholar
• Roskoski, R. Jr. (2022). Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological Research, 175, 106037. https://doi.org/10.1016/j.phrs.2021.106037
   PubMed Web of Science ®Google Scholar
• Schrodinger Release 2021-2 (2021a). LigPrep. Schrodinger, LLC.
   Google Scholar
• Schrodinger Release 2021-2 (2021b). Prime. Schrodinger, LLC.
   Google Scholar
• Schrodinger Release 2021-2 (2021c). Desmond molecular dynamics system. D. E. Shaw Research. Maestro-Desmond interoperability tools. Schrodinger.
   Google Scholar
• Schrodinger Release 2021-2 (2021d). Maestro. Schrodinger, LLC.
   Google Scholar
• Sterling, T., & Irwin, J. J. (2015). ZINC 15–Ligand discovery for everyone. Journal of Chemical Information and Modeling, 55(11), 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559
   PubMed Web of Science ®Google Scholar
• Sullivan, I., & Planchard, D. (2016). Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Frontiers in Medicine, 3, 76. https://doi.org/10.3389/fmed.2016.00076
   PubMed Web of Science ®Google Scholar
• Tripathi, S. K., & Biswal, B. K. (2021). Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma. Drug Discovery Today, 26(6), 1466–1472. https://doi.org/10.1016/j.drudis.2021.02.005
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., Tao, H., Zhu, S., Iwanami, A., Kuga, D., Dang, J., Pedraza, A., Brennan, C. W., Heguy, A., Liau, L. M., … Mellinghoff, I. K. (2012). Differential sensitivity of glioma versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery, 2(5), 458–471. https://doi.org/10.1158/2159-8290.CD-11-0284
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A. Jr., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546–1558. https://doi.org/10.1126/science.1235122
   PubMed Web of Science ®Google Scholar
• Wang, S., & Khan, F. I. (2023). Investigation of molecular interactions mechanism of pembrolizumab and PD-1. International Journal of Molecular Sciences, 24(13), 10684. https://doi.org/10.3390/ijms241310684
   PubMed Web of Science ®Google Scholar